Risks and management of pregnancy in women with epilepsy

Cleveland Clinic Journal of Medicine

Volumn 71, Issue SUPPL. 2, 2004, Pages

  Yerby, Mark S ^a,d   Kaplan, Peter ^b   Tran, Teresa ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MINCEP Epilepsy Care   (United States)

^d North Pacific Epilepsy Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

BENIGN CHILDHOOD EPILEPSY; CONGENITAL MALFORMATION; DISEASE EXACERBATION; EPILEPSY; FETUS WASTAGE; GESTATIONAL AGE; GROWTH RETARDATION; HUMAN; LOW BIRTH WEIGHT; NEONATAL HEMORRHAGE; PERINATAL DEATH; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; REVIEW; TREATMENT PLANNING; BREAST FEEDING; FEMALE; PATHOPHYSIOLOGY; PREGNANCY OUTCOME; RISK;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; BREAST FEEDING; EPILEPSY; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK;

EID: 4944222781     PISSN: 08911150     EISSN: 08911150     Source Type: Journal    
DOI: 10.3949/ccjm.71.suppl_2.s25     Document Type: Review

References (121)

1. Cahill WT, Kovilam OP, Pastor D, et al. Neurologic and fetal outcomes of pregnancies of mothers with epilepsy. Epilepsia 2002; 43(suppl 7):289. Abstract.
2. Nau H, Kuhnz W, Egger HJ, Rating D, Helge H. Anticonvulsants during pregnancy and lactation. Transplacental maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982; 7:508-543.
3. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994; 35:122-130.
4. Rodriguez-Palomares C, Belmont-Gomez A, Amancio-Chassin O, Estrada-Altamirano A, Herrerias-Cunedo T, Hernandez-Serrano M. Phenytoin serum concentration monitoring during pregnancy and puerperium in Mexican epileptic women. Arch Med Res 1995; 26:371-377.
5. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38:1039-1041.
6. Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002; 59:251-255.
7. Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990; 5:223-228.
8. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41:709-713.
9. Dansky LV, Andermann E, Andermann F, Sherwin AL, Kinch RA. Maternal epilepsy and congenital malformations: Correlations with maternal plasma anticonvulsant levels during pregnancy. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy and the Child. New York: Raven Press; 1982:251-258.
10. Janz D. Antiepileptic drugs and pregnancy: altered utilization patterns and teratogenesis. Epilepsia 1982; 23(suppl 1):S53-S63.
11. Schmidt D. The effect of pregnancy on the natural history of epilepsy: a review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy and the Child. New York: Raven Press; 1982:3-14.
12. Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983; 46:751-755.
13. Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 1985; 39:33-41.
14. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982; 7:336-352.
15. Dam M, Christiansen J, Munck O, Mygind KI. Antiepileptic drugs: metabolism in pregnancy. Clin Pharmacokinet 1979; 4:53-62.
16. Philbert A, Dam M. The epileptic mother and her child. Epilepsia 1982; 23:85-99.
17. Stumpf DA, Frost M. Seizures, anticonvulsants, and pregnancy. Am J Dis Child 1978; 132:746-748.
18. Leonard G, Andermann E, Schopflocker C. Cognitive effects of antiepileptic drug therapy during pregnancy on school-age offspring. Epilepsia 1997; 38(suppl 3):170. Abstract.
19. Burnett CWF. A survey of the relation between epilepsy and pregnancy. J Obstet Gynecol 1946; 53:539-556.
20. Higgins TA, Comerford JB. Epilepsy in pregnancy. J Ir Med Assoc 1974; 67:317-320.
21. Suter C, Klingman WO. Seizure states and pregnancy. Neurology 1957; 7:105-118.
22. Teramo K, Hiilesmaa VK. Pregnancy and fetal complications in epileptic pregnancies: review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy and the Child. New York: Raven Press; 1982:53-59.
23. Minkoff H, Schaffer RM, Delke I, Grunebaum AN. Diagnosis of intracranial hemorrhage in utero after a maternal seizure. Obstet Gynecol 1985; 65(suppl):22S-24S.
24. Teramo K, Hiilesmaa V, Bardy A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7:3-6.
25. Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985; 26:631-635.
26. Yerby MS, Cawthon ML. Fetal death, malformations and infant mortality in infants of mothers with epilepsy. Epilepsia 1996; 37(suppl 5):98. Abstract.
27. Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for spontaneous abortion. Epilepsia 1997; 38:824-829.
28. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. Br Med J 1973; 2:442-148.
29. Kelly TE. Teratogenicity of anticonvulsant drugs. I: Review of the literature. Am J Med Genet 1984; 19:413-134.
30. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21:663-680.
31. Steegers-Theunissen RP, Renier WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Res 1994; 18:261-269.
32. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997; 17:561-564.
33. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepilcptic drugs. Epilepsy Res 1999; 3:145-158.
34. Friis ML, Holm NV, Sindrup EH, Fogh-Andersen P, Hauge M. Facial clefts in sibs and children of epileptic patients. Neurology 1986; 36:346-350.
35. Abrishamchian AR, Khoury MJ, Calle EE. The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case-control study. Genet Epidemiol 1994; 11:343-351.
36. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42(supp15):111-118.
37. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2:937.
38. Robert E, Lofkvist E, Mauguiere F, Robert JM. Evaluation of drug therapy and teratogenic risk in a Rhone-Alpes district population of pregnant epileptic women. Eur Neurol 1986; 25:436-443.
39. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324:674-677.
40. Little BB, Santos-Ramos R, Newell JF, Maberry MC. Megadose carbamazepine during the period of neural tube closure. Obstet Gynecol 1993; 82(4 Pt 2 suppl):705-708.
41. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; 1:1392-1393.
42. Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology 1992;42(suppl 5):8-11.
43. Omtzigt JG, Los FJ, Hagenaars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn 1992; 12:893-897.
44. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988; 260:3141-3145.
45. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001; 285:2981-2986.
46. Harris JA, Shaw GM. Neural tube defects-why are rates high among populations of Mexican descent? Environ Health Perspect 1995; 103(suppl 6):163-164.
47. Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 1990; 85:1-9.
48. Blatter BM, Roeleveld N, Zielhuis GA, Mullaart RA, Gabreels FJ. Spina bifida and parental occupation. Epidemiology 1996; 7:188-193.
49. Matte TD, Mulinare J, Erickson JD. Case-control study of congenital defects and parental employment in health care. Am J Ind Med 1993; 24:11-23.
50. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996; 275:1127-1128.
51. Dansky LV, Strickler SM, Andermann E, Miller MA, Seni MH, Spielberg SP. Pharmacogenetic susceptibility to phenytoin teratogenesis. In: Wolf P, Dam M, Janz D, Dreifuss FE, eds. Advances in Epileptology, Vol. 16. The XVIth Epilepsy International Symposium. New York: Raven Press; 1987:555-559.
52. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984; 18:211-216.
53. Zhu MX, Zhou SS. Reduction of the teratogenic effects of phenytoin by folic acid and a mixture of folic acid, vitamins, and amino acids: a preliminary trial. Epilepsia 1989; 30:246-251.
54. Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999; 8:253-254.
55. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001; 42:750-753.
56. Mills JL, Tuomilehto J, Yu KF, et al. Maternal vitamin levels during pregnancies producing infants with neural tube defects. J Pediatr 1992; 120:863-671.
57. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 1981; 282:1509-1511.
58. Winship KA, Cahal DA, Weber JC, Griffin JP. Maternal drug histories and central nervous system anomalies. Arch Dis Child 1984; 59:1052-1060.
59. Vergel RG, Sanchez LR, Heredero BL, Rodriguez PL, Martinez AJ. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn 1990; 10:149-152.
60. Kirke PN, Daly LE, Elwood JH. A randomised trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group. Arch Dis Child 1992; 67:1442-1446.
61. Bower C, Stanley FJ. Periconceptional vitamin supplementation and neural tube defects; evidence from a case-control study in Western Australia and a review of recent publications. J Epidemiol Community Health 1992; 46:157-161.
62. Friel JK, Frecker M, Fraser FC. Nutritional patterns of mothers of children with neural tube defects in Newfoundland. Am J Med Genet 1995; 55:195-199.
63. Oakley GP Jr. Folic-acid-preventable spinn bifida and anencephaly. Bull World Health Organ 1998; 76(suppl 2):116-117.
64. Jerina DM, Daly JW. Arene oxides: a new aspect of drug metabolism. Science 1974; 185:573-582.
65. Sims P, Grover PL. Epoxides in polycyclic aromatic hydrocarbon metabolism and carcinogenesis. Adv Cancer Res 1974; 20:165-274.
66. Nebert DW, Jensen NM. The Ah locus: genetic regulation of the metabolism of carcinogens, drugs, and other environmental chemicals by cytochrome P-450-mediated monooxygenases. CRC Crit Rev Biochem 1979; 6:401-437.
67. Shum S, Jensen NM, Nebert DW. The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism. Teratology 1979; 20:365-376.
68. Pacifici GM, Colizzi C, Giuliani L, Rane A. Cytosolic epoxide hydrolase in fetal and adult human liver. Arch Toxicol 1983; 54:331-341.
69. Pacifici GM, Rane A. Metabolism of styrene oxide in different human fetal tissues. Drug Metab Dispos 1982; 10:302-305.
70. Finnell RH, DiLiberti JH. Hydantoin-induced teratogenesis: are arene oxide intermediates really responsible? Helv Paediatr Acta 1983; 38:171-177.
71. Wells PG, Kupfer A, Lawson JA, Harbison RD. Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol. J Pharmacol Exp Ther 1982; 221:228-234.
72. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37:489-497.
73. Baptisti A. Epilepsy and pregnancy. Am J Obstet Gynecol 1938; 35:818-824.
74. Gaily E, Granstrom ML, Hiilesmaa V, Bardy A. Minor anomalies in offspring of epileptic mothers. J Pediatr 1988; 112:520-529.
75. Gaily E, Kantala-Sorsa E, Granttstrom ML. Intelligence of children of epileptic mothers. J Pediatr 1988; 113:677-684.
76. Neri A, Heifetz L, Nitke S, et al. Neonatal outcomes in infants of epileptic mothers. Eur J Obstet Gynecol Reprod Biol 1983; 16:263-268.
77. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29:459-467.
78. Dieterich E, Steveling A, Lukas A, Seyfeddinipur N, Spranger J. Congenital anomalies in children of epileptic mothers and fathers. Neuropediatrics 1980; 11:274-283.
79. Vorhees CV. Developmental effects of anticonvulsants. Neurotoxicology 1986; 7:235-244.
80. Huot C, Gauthier M, Lebel M, Larbisseau A. Congenital malformations associated with maternal use of valproic acid. Can J Neurol Sci 1987; 14:290-293.
81. Van Creveld S. Nouveaux aspects de la maladie hemorragique du nouveau né. Ned Tijdschr Geneeskd 1957; 101:2109.
82. Mountain KR, Hirsh J, Gallus AS. Maternal coagulation defect due to anticonvulsant treatment in pregnancy. Lancet 1970; 1:265-268.
83. Lawerence A. Anti-epileptic drugs and the foetus. Br Med J 1963; 1:1267.
84. Douglas H. Haemorrhage in the newborn. Lancet 1966; 1:816-817.
85. Kohler HG. Haemorrhage in the newborn of epileptic mothers. Lancet 1966; 1:267.
86. Solomon GE, Hilgartner MW, Kutt H. Coagulation defects caused by diphenylhydantoin. Neurology 1972; 22:1165-1177.
87. Bleyer WA, Skinner AL. Fatal neonatal hemorrhage after maternal anticonvulsant therapy. JAMA 1976; 235:626-627.
88. Griffiths AD. Neonatal haemorrhage associated with maternal anticonvulsant therapy. Lancet 1981; 2:1296-1297.
89. Srinivasan G, Seeler RA, Tiruvury A, Pildes RS. Maternal anticonvulsant therapy and hemorrhagic disease of the newborn. Obstet Gynecol 1982; 59:250-252.
90. Davies VA, Rothberg AD, Argent AC, Atkinson PM, Staub H, Pienaar NL. Precursor prothombin status in patients receiving anticonvulsant drugs. Lancet 1985; 1:126-128.
91. Walker NP, Bardlow BA, Atkinson PM. A rapid chromogenic method for the determination of prothrombin precursor in the plasma. Am J Clin Pathol 1982; 78:777-780.
92. Argent AC, Rothberg AD, Pienaar N. Precursor prothrombin status in mother-infant pairs following gestational anticonvulsant therapy. Pediatr Pharmacol 1984; 4:183-187.
93. Deblay MF, Vert P, Andre M, Marchal F. Transplacental vitamin K prevents hemorrhagic disease of infants of epileptic mothers. Lancet 1982; 1:1247.
94. Cornelissen M, Steegers-Theunissen R, Kollee L, Eskes T, Motohara K, Mommens L. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993; 168(3 pt 2):884-888.
95. 1 (phylloquinone) supplementation replace prophylaxis at birth? Obstet Gynecol 1993; 81:251-254.
96. Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002; 58:549-553.
97. Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation. Arch Dis Child Fetal Neonatal Ed 1999; 81:F208-F210.
98. Shapiro AD, Jacobson LJ, Armon ME, et al. Vitamin K deficiency in the new-born infant: prevalence and perinatal risk factors. J Pediatr 1986; 109:675-680.
99. Svigos JM. Epilepsy and pregnancy. Aust N Z J Obstet Gynaecol 1984; 24:182-185.
100. Annegers JF, Elveback LR, Hauser WA, Kurland LT. Do anticonvulsants have a teratogenic effect? Arch Neurol 1974; 31:364-373.
101. Hvas CL, Henriksen TB, Ostergaard JR, Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birth-weight. BJOG 2000; 107:896-902.
102. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and the newborn. Lancet 1972; 2:839-843.
103. Hill RM, Tennyson L. Premature delivery, gestational age, complications of delivery, vital data at birth on newborn infants of epileptic mothers: review of the literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy and the Child. New York: Raven Press; 1982:167-173.
104. Leavitt AM, Yerby MS, Robinson N, Sells CJ, Erickson DM. Epilepsy and pregnancy: developmental outcomes at 12 months. Neurology 1992; 42(suppl 5):141-143.
105. Losche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994; 83:961-966.
106. Koch S, Titze K, Zimmermann RB, Schroder M, Lehmkuhl U, Rauh H. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40:1237-1243.
107. Annegers JF, Hauser WA, Elveback LR, Anderson VE, Kurland LI. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978; 7:241-247.
108. Ottman R, Annegers JF, Hauser WA, Kurland LT. Higher risk of seizures in offspring of mothers than of fathers with epilepsy. Am J Hum Genet 1988; 43:257-264.
109. Holmes GL, Weber DA. Effect of seizures during pregnancy on seizure susceptibility in offspring. Epilepsia 1985; 26:421-423.
110. Montouris G. Safety of gabapentin treatment during pregnancy. Epilepsia 2002; 43(suppl 7):234. Abstract.
111. Tennis P, Eldridge RR. Preliminary results on pregnancy outcomes in women using lamotrigine. Scientific Advisory Committee. International Lamotrigine Pregnancy Registry. Epilepsia 2002; 43:1161-1167.
112. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87:224-227.
113. Rabinowicz A, Meischenfuiser R, Ferraro SM, D'Giano CH, Carrazana EJ. Single-center 7 year experience of oxcarbazepine exposure during pregnancy. Epilepsia 2002; 43(suppl 7):208-209. Abstract.
114. Myllynen P, Pienimaki P, Jouppila P, Vahakangas K. Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia 2001; 42:1482-1485.
115. Ohman I, Vitols S, Luef G, Soderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002; 43:1157-1160.
116. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37:1242-1244.
117. Kawada K, Itoh S, Kusaka T, Isobe K, Ishii M. Pharmacokinetics of zonisamide in perinatal period. Brain Dev 2002; 24:95-97.
118. Schachter SC, Schmidt D, eds. Vagus nerve stimulation. London: Martin Dunitz; 2000:11.
119. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983; 1:1027-1031.
120. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-137.
121. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-1835.